3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Genitourinary
1
Breast
1
Conditions
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Venous Thrombosis
1
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Sorafenib
222
lenvatinib
147
Bevacizumab
131
Nivolumab
87
atezolizumab
81
pembrolizumab
74
Radiosurgery
71
durvalumab
63
sintilimab
61
Oxaliplatin
60
Fluorouracil
56
Doxorubicin
47
tislelizumab
46
apatinib
45
Radiofrequency Ablation
44
Hepatectomy
43
camrelizumab
41
Leucovorin
41
Radiotherapy
40
tremelimumab
37
Magnetic Resonance Spectroscopy
36
regorafenib
34
Capecitabine
30
Immune Checkpoint Inhibitors
29
Folfox protocol
29
Cisplatin
28
cabozantinib
26
Gemcitabine
26
Cyclophosphamide
26
Ipilimumab
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Rivaroxaban
×
Gastrointestinal
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled